• Explore /
  • Poster
  • / A phase Ib/II, multicenter, open-label, dose-escalation, and dose-expansion study evaluating trastuzumab deruxtecan (T-DXd, DS-8201) monotherapy and combinations in patients with HER2-overexpressing gastric cancer (DESTINY-Gastric03).

A phase Ib/II, multicenter, open-label, dose-escalation, and dose-expansion study evaluating trastuzumab deruxtecan (T-DXd, DS-8201) monotherapy and combinations in patients with HER2-overexpressing gastric cancer (DESTINY-Gastric03).

Abstract Poster

Authors

Yelena Janjigian

Yelena Y. Janjigian

Memorial Sloan Kettering Cancer Center, New York, NY

Yelena Y. Janjigian , Natasha Viglianti , Feng Liu , Ariadna Mendoza-Naranjo , Liz Croydon

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 Gastrointestinal Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session: Esophageal and Gastric Cancer

Track

Esophageal and Gastric Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT04379596

Citation

J Clin Oncol 39, 2021 (suppl 3; abstr TPS261)

DOI

10.1200/JCO.2021.39.3_suppl.TPS261

Abstract #

TPS261

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Yelena Y. Janjigian

First Author: Yelena Y. Janjigian

First Author: Charles S. Fuchs

First Author: Zhi Peng